John Kaczmar to Neoadjuvant Therapy
This is a "connection" page, showing publications John Kaczmar has written about Neoadjuvant Therapy.
Connection Strength
0.102
-
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2022 04 01; 28(7):1345-1352.
Score: 0.052
-
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100426.
Score: 0.050